Get the Stockscreener App
4.76
1.04%
-0.05
After Hours:
4.76
Evoke Pharma Inc stock is traded at $4.76, with a volume of 17,405.
It is down -1.04% in the last 24 hours and up +10.96% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$4.81
Open:
$4.7401
24h Volume:
17,405
Relative Volume:
0.27
Market Cap:
$3.81M
Revenue:
$5.18M
Net Income/Loss:
$-7.79M
P/E Ratio:
-2.0169
EPS:
-2.36
Net Cash Flow:
$-4.99M
1W Performance:
-9.51%
1M Performance:
+10.96%
6M Performance:
-34.97%
1Y Performance:
-71.26%
1-Day Range:
$4.56
$5.05
1-Week Range:
$4.56
$5.35
52-Week Range:
$3.54
$18.00
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma amends warrants, secures $2.4 million funding By Investing.com - Investing.com South Africa
Evoke Pharma amends warrants, secures $2.4 million funding By Investing.com - Investing.com Canada
Evoke Pharma amends warrants, secures $2.4 million funding By Investing.com - Investing.com UK
Long Term Trading Analysis for (EVOK) - Stock Traders Daily
Gastroparesis Treatment Market From Present to Future: Dynamic Growth Factors Transforming Industries by 2031 - WhaTech
Diabetic Gastroparesis Market Analysis 2024-2031 - Apiculture Market: Report ...
Evoke Pharma stands by GI treatment after FDA decision - Investing.com Australia
Evoke Pharma stands by GI treatment after FDA decision - Investing.com India
US FDA issues CRL for Vanda’s tradipitant for gastroparesis - BioWorld Online
Evoke Pharma stands by GI treatment after FDA decision - Investing.com
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments - ForexTV.com
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments - GlobeNewswire
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments - StockTitan
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments - Yahoo Finance
StockNews.com Begins Coverage on China Pharma (NYSE:CPHI) - Defense World
Entain (LON:ENT) PT Raised to GBX 1,030 at Berenberg Bank - Defense World
Gastroparesis Market Size is Set for Rapid Growth as Innovative - openPR
Digestive and Intestinal Remedies Market Size, Opportunities By 2033 In New Report - WhaTech
Intranasal Drug Delivery Research Report 2024: Global Market to Reach $92.6 Billion by 2030Controlled - Daily Guardian Canada
Questex’s Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards Winners - GlobeNewswire Inc.
Intranasal Drug Delivery Research Report 2024: Global Market to Reach $92.6 Billion by 2030Controlled Release Technology is the New Buzz Word - 24matins.uk
Intranasal Drug Delivery Research Report 2024: Global - GlobeNewswire
Digestive Health Market Report 2024: Comprehensive Insights on Market Growth, Key Trends, and Innovations - WhaTech
Diabetic Gastroparesis Market Insights, Epidemiology, and Market Forecast 2032 by Delveinsight - openPR
Gastroparesis Treatment Market Growth and Future Outlook Industry Insights: Market Size, Share, and Forecast - EIN News
Gilead's Trodelvy triplet underwhelms, but exec says data bolster company's phase 3 lung cancer design - FiercePharma
Evoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.com - Defense World
Evoke Pharma to Participate in Gastroenterology and - GlobeNewswire
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference - StockTitan
Evoke Pharma stock hits 52-week low at $3.74 amid market challenges - Investing.com
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference - ForexTV.com
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference - GlobeNewswire
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference - Yahoo Finance UK
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference - StockTitan
StockNews.com Initiates Coverage on The LGL Group (NYSE:LGL) - Defense World
Trend Tracker for (EVOK) - Stock Traders Daily
Short Interest in CK Asset Holdings Limited (OTCMKTS:CHKGF) Decreases By 38.8% - Defense World
Hims & Hers Health (NYSE:HIMS) Shares Gap Down to $16.05 - Defense World
Harbour Investments Inc. Has $613,000 Stake in Hartford Schroders Tax-Aware Bond ETF (NYSEARCA:HTAB) - Defense World
Harbour Investments Inc. Has $612,000 Holdings in Enbridge Inc. (NYSE:ENB) - Defense World
Criteo (NASDAQ:CRTO) Shares Gap Down to $49.66 - Defense World
Tilray (NASDAQ:TLRY) Sees Large Volume Increase - Defense World
Star Bulk Carriers (NASDAQ:SBLK) Shares Gap Down to $21.58 - Defense World
Abercrombie & Fitch’s (ANF) Outperform Rating Reaffirmed at Telsey Advisory Group - Defense World
Hut 8 (NASDAQ:HUT) Stock Price Down 4.4% - Defense World
Diabetic Gastroparesis Treatment Market Business Growth, Opportunities, Future Prediction Report By 2031 - openPR
iShares U.S. Infrastructure ETF (BATS:IFRA) Shares Sold by Concourse Financial Group Securities Inc. - Defense World
Concourse Financial Group Securities Inc. Reduces Holdings in Schwab Fundamental International Large Company Index ETF (NYSEARCA:FNDF) - Defense World
Concourse Financial Group Securities Inc. Increases Stock Position in JP Morgan BetaBuilders U.S. Equity ETF (BATS:BBUS) - Defense World
Rapid Demand in Gastroparesis Treatment Market 2024 Trends, - openPR
Antinauseants Industry to Witness Massive Growth (2024-2031) | - openPR
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):